Predictors of Response to Therapy for Chronic Hepatitis C

Pretreatment prediction of successful interferon-based therapy is less accurate than is prediction based on serum hepatitis C virus (HCV) RNA measurements taken during the first few weeks of therapy. Virological response, defined as loss of detectable virus RNA during the first weeks of treatment, identifies interferon-sensitive virus strains. Studies on viral decline kinetics have shown that interferon-based therapies produce a two-phase reduction in viral RNA levels. Sustained virological response is associated with rapid biphasic viral decline kinetics, resulting in elimination of virus from the blood within 4 to 12 weeks. Rapid viral elimination correlates positively with low incidence of relapse in end-of-treatment virological responders and is, therefore, an important parameter for determining duration or type of therapy. This article reviews the various patient and viral factors that help predict response to various interferon-based therapies, ranging from interferon alone to the new pegylated interferons.

Prediction - chronic hepatitis C - viral kinetics - interferon - ribavirin

REFERENCES

• 1 Davis G L, Lau J Y. Factors predictive of a beneficial response to therapy of hepatitis C.  Hepatology. 1997;  26 122S-127S
• 2 National Institutes of Health . National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C.  Hepatology. 1997;  26 2S-10S
• 3 McHutchison J, Gordon S, Schiff E et al.. Interferon alfa 2B alone or in combination with ribavirin in naive chronic HCV patients: a US multicenter trial.  Hepatology. 1998;  28 387
• 4 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.  Lancet. 1998;  352 1426-1432
• 5 Lee S S, Heathcote E J, Reddy K R et al.. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).  J Hepatol. 2002;  37 500-506
• 6 Poynard T, McHutchison J, Goodman Z et al.. Is an a la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?.  Hepatology. 2000;  31 211-218
• 7 Zeuzem S, Feinman S V, Rasenack J et al.. Peginterferon alfa-2a in patients with chronic hepatitis C.  N Engl J Med. 2000;  343 1666-1672
• 8 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 9 Lindsay K L, Trepo C, Heintges T et al.. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.  Hepatology. 2001;  34 395-403
• 10 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
• 11 Izopet J, Payen J L, Alric L et al.. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.  J Med Virol. 1998;  54 86-91
• 12 Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon.  J Hepatol. 2001;  35 307
• 13 Di Bisceglie A M, Bonkovsky H L, Chopra S et al.. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.  Hepatology. 2000;  32 135-138
• 14 Thorburn D, Curry G, Spooner R et al.. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.  Gut. 2002;  50 248-252
• 15 Schalm S W, Fattovich G, Brouwer J T. Therapy of hepatitis C: patients with cirrhosis.  Hepatology. 1997;  26 128S-132S
• 16 Kaserer K, Fiedler R, Steindl P et al.. Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.  Histopathology. 1998;  32 454-461
• 17 Everson G T, Jensen D M, Craig J R et al.. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.  Hepatology. 1999;  30 271-276
• 18 Heathcote E J, Shiffman M L, Cooksley W G et al.. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.  N Engl J Med. 2000;  343 1673-1680
• 19 Cerny A, Chisari F V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.  Hepatology. 1999;  30 595-601
• 20 Nelson D R, Marousis C G, Ohno T, Davis G L, Lau J YN. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.  Hepatology. 1998;  28 225-230
• 21 Larrea E, Garcia N, Qian C, Civeira M P, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.  Hepatology. 1996;  23 210-217
• 22 Cacciola I, Pollicino T, Squadrito G et al.. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med. 1999;  341 22-26
• 23 Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.  Clin Infect Dis. 1996;  23 1117-1125
• 24 Soriano V, Sulkowski M, Bergin C et al.. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.  AIDS. 2002;  16 813-828
• 25 Sterling R K, Sulkowski M S. HCV in the setting of HIV or HBV coinfection.  Semin Liver Dis. 2004;  24 61-68
• 26 Hoofnagle J H. Hepatitis C: the clinical spectrum of disease.  Hepatology. 1997;  26 15S-20S
• 27 Lawrence S P. Advances in the treatment of hepatitis C.  Adv Intern Med. 2000;  45 65-105
• 28 Doglio A, Laffont C, Caroli-Bosc F X, Rochet P, Lefebvre J C. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant.  J Clin Microbiol. 1999;  37 1567-1569
• 29 Martinot-Peignoux M, Boyer N, Le Breton V et al.. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.  Hepatology. 2000;  31 726-729
• 30 Hadziyannis S J, Cheinquer H, Morgan T et al.. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose.  J Hepatol. 2002;  36 3
• 31 Farci P, Strazzera R, Alter H J et al.. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.  Proc Natl Acad Sci USA. 2002;  99 3081-3086
• 32 Podevin P, Sabile A, Gajardo R et al.. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR- independent manner.  Hepatology. 2001;  33 1503-1511
• 33 National Institutes of Health . National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002.  Hepatology. 2002;  36(Suppl 1) S3-S20
• 34 Bain V G. Effect of HCV viral dynamics on treatment design: lessons learned from HIV.  Am J Gastroenterol. 2001;  96 2818-2828
• 35 Zeuzem S, Schmidt J M, Lee J H, Ruster B, Roth W K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.  Hepatology. 1996;  23 366-371
• 36 Neumann A U, Lam N P, Dahari H et al.. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.  Science. 1998;  282 103-107
• 37 Zeuzem S, Schmidt J M, Lee J H et al.. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.  Hepatology. 1998;  28 245-252
• 38 Herrmann E, Neumann A U, Schmidt J M, Zeuzem S. Hepatitis C virus kinetics.  Antivir Ther. 2000;  5 85-90
• 39 Neumann A U, Lam N P, Dahari H et al.. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.  J Infect Dis. 2000;  182 28-35
• 40 Zeuzem S, Herrmann E, Lee J H et al.. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a.  Gastroenterology. 2001;  120 1438-1447
• 41 Boyer N, Marcellin P. Natural history of hepatitis C and the impact of anti-viral therapy.  Forum. 2000;  10 4-18
• 42 Bergmann C C, Layden J E, Levy-Drummer R S et al.. Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-a therapy.  Hepatology. 2001;  34 345A
• 43 Bekkering F C, Brouwer J T, Leroux-Roels G et al.. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.  J Hepatol. 1998;  28 960-964
• 44 Zeuzem S, Lee J H, Franke A et al.. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.  Hepatology. 1998;  27 1149-1156
• 45 Bekkering F C, Brouwer J T, Schalm S W, Elewaut A. Hepatitis C: viral kinetics.  Hepatology. 1997;  26 1691-1693
• 46 Jessner W, Gschwantler M, Steindl-Munda P et al.. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.  Lancet. 2001;  358 1241-1242
• 47 Ferenci P, Shiffman M, Fried M et al.. Early prediction of response to 40 kDa peginterferon alfa-2a (PEGASYS®) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC).  Hepatology. 2001;  34 351A
• 48 Jessner W, Stauber R, Hackl F et al.. Early viral kinetics on treatment with pegylated interferon α-2a in chronic hepatitis C genotype 1 infection.  J Viral Hepat. 2003;  10 37-42
• 49 Davis G L. Monitoring of viral levels during therapy of hepatitis C.  Hepatology. 2002;  36 S145-S151
• 50 Neumann A U, Zeuzem S, Brunda M J. Rapid viral response to treatment with pegylated (40KDA) interferon alfa-2a (Pegasys TM) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C.  Hepatology. 2000;  32 318A
• 51 Peg-Intron package insert Kenilworth, NJ; Schering Corp 2001
• 52 Herxenberg L A, Moore W A, De Rosa S C. Estimation of missing values.  Lancet. 1999;  354 686
• 53 McHutchison J G, Manns M, Patel K et al.. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.  Gastroenterology. 2002;  123 1061-1069
• 54 Civeira M P, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C.  J Hepatol. 1999;  31 237-243
• 55 McHutchison J G, Shad J A, Gordon S C et al.. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy.  J Viral Hepat. 2001;  8 414-420